Rocket


News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Genfit S.A. (GNFT) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/26/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"GENFIT | Press relations Stephanie Boyer | Tel: +333 2016 4000 | [email protected] 4"
08/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Press Release"
07/12/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Number of executions Number of shares Traded amounts in EUR Number of executions Number of shares Traded amounts in EUR"
06/30/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"GENFIT will host a conference call on June 30, 2023 at 8:00am ET / 1:00pm GMT / 2:00pm CET in English and in French Both the English and French conference calls will be accessible on the investor page of our website, under the events section at https://ir.genfit.com/ or by calling 888-394-8218 , 0800 279 0425 or 0805 101 219 five minutes prior to the start time . A replay will be available shortly after the call. ABOUT ELAFIBRANOR Elafibranor is a novel, oral, once-daily, dual peroxisome activated receptor alpha/delta agonist, currently under investigation as a treatment for patients with PBC, a rare liver disease. In 2019, it was granted a Breakthrough Therapy designation by the FDA in adults with PBC who have an inadequate response to ursodeoxycholic acid . Elafibranor has not received a..."
06/07/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"GENFIT | Investors"
05/31/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"33 3 20 16 40"
05/24/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"GENFIT"
05/23/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"GENFIT"
05/11/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"GENFIT | Investors"
05/09/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"GENFIT | Investors Tel: +33 3 2016 4000 | [email protected] PRESS RELATIONS | Media Stephanie Boyer – Press relations | Tel: +33 3 2016 4000 | [email protected]"
05/05/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/28/2023 6-K Quarterly results
04/19/2023 6-K Quarterly results
04/18/2023 6-K Quarterly results
04/18/2023 F-3 Form F-3 - Registration statement by foreign private issuers:
04/18/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
04/18/2023 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
04/14/2023 6-K Quarterly results
02/28/2023 6-K Quarterly results
01/30/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"01/07/20 22 18 2832 8 636,41 13 2469 7 579,59 04/07/20 22 15 2808 8 691,55 26 8288 25 737,37 05/07/20 22 26 7955 25 355,01 29 20374 65 398,59 06/07/20 22 16 4220 13 276,05 12 2554 8 074,20 07/07/20 22 6 1292 4 214,35 24 8899 28 843,38 08/07/20 22 2 353 1 147,97 3 353 1 155,01 11/07/20 22 23 4786 16 105,83 60 12921 44 025,39 12/07/20 22 94 20252 70 347,19 58 13230 46 243,87 13/07/20 22 42 10361 35 632,51 75 14935 51 843,11 14/07/20 22 51 7594 26 838,57 55 8492 30 277,12 15/07/20 22 24 5592 20 168,69 27 6489 23 669,94 18/07/20 22 9 1389 5 408,47 15 2212 8 634,27 19/07/20 22 27 8839 34 172,53 38 13773 54 079,10 20/07/20 22 24 7265 28 590,78 17 3085 12 212,57 21/07/20 22 34 8808 34 820,54 41 11812 46 866,87 22/07/20 22 32 22153 89 152,26 28 18909 76 315,28 25/07/20 22 12 14922 59 574,53 19 134..."
01/24/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"GENFIT | Investors Tel: +33 3 2016 4000 | [email protected] PRESS RELATIONS | Media Stephanie Boyer – Press relations | Tel: +333 2016 4000 | [email protected]"
01/05/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"GENFIT | Investors Tel: +33 3 2016 4000 | [email protected] PRESS RELATIONS | Media Stephanie Boyer – Press relations | Tel: +333 2016 4000 | [email protected] 3"
11/17/2022 6-K Quarterly results
11/10/2022 6-K Quarterly results
10/25/2022 6-K Quarterly results
09/29/2022 6-K Quarterly results
09/28/2022 6-K Quarterly results
09/19/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"GENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis, expanding its Portfolio in Liver Diseases § Further consolidates GENFIT’s position as a leader in acute-on-chronic liver failure § Significantly expands GENFIT’s pipeline with VS-01-ACLF, a Phase 2 ready program based on first-in-class scavenging liposomes technology, VS-01-UCD, a pediatric program focused on urea cycle disorder , and VS-02-HE, an early-stage program focused on hepatic encephalopathy § Combines Versantis’ expertise with GENFIT’s know-how in conducting complex development programs in liver diseases, to strengthen and accelerate research and development § Deal terms include a payment of CHF40 million, an aggregate of CHF65 million of potential additional payments contingent on successfu..."
09/13/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"FDA Grants GENFIT’s GNS561 Orphan Drug Designation for the Treatment of Cholangiocarcinoma"
07/08/2022 6-K Quarterly results
05/25/2022 6-K Quarterly results
05/11/2022 6-K Quarterly results
04/29/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"GENFIT Announces Publication of the 2021 Universal Registration Document; the 2021 Annual Report on Form 20-F and Availability of Preparatory Documents for the Annual Combined Shareholders Meeting on May 25, 2022"
04/29/2022 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy